EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients

Alyssa A Toorop iD, Mark Hj Wessels iD, Lynn Boonkamp, Liza My Gelissen, E Hoitsma, Esther Mpe Zeinstra, Luuk C van Rooij, Caspar Ep van Munster, Anke Vennegoor, Jop P Mostert, Beatrijs Ha Wokke iD, Nynke F Kalkers und 20 weitere

Multiple Sclerosis Journal · 2024

DOI: 10.1177/13524585241293940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Alyssa A Toorop und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Neurofilament Proteins, Natalizumab, Glial Fibrillary Acidic Protein, Biomarkers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting MS Research, Hersenstichting, Innovative Medicines Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs).

Objectives

We investigated the longitudinal association between and predictive value of sNfL and sGFAP and the occurrence of WoS in MS patients treated with natalizumab.

Methods

We performed longitudinal measurements of sNfL and sGFAP in NEXT-MS trial participants who completed a questionnaire about WoS.

Results

A total of 364 participants were included. In total, 55.5% presented with WoS and 44.5% without WoS during natalizumab treatment. Longitudinal analyses showed no association between sNfL and sGFAP levels and WoS at any timepoint. Biomarker levels at baseline did not predict first-time WoS occurrence.

Conclusion

Acute and chronic neuronal and axonal damage are most likely not the underlying cause of WoS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofilament ProteinsNatalizumabGlial Fibrillary Acidic ProteinBiomarkersImmunologic FactorsHumansFemaleMaleAdultMiddle AgedLongitudinal StudiesMultiple SclerosisMultiple Sclerosis, Relapsing-Remitting

Stichwörter der Autor:innen

Multiple sclerosisbiomarkersnatalizumabtreatment response

Substanzen

Neurofilament ProteinsNatalizumabneurofilament protein LGlial Fibrillary Acidic ProteinBiomarkersGFAP protein, humanImmunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Department of Neurology, MS Center Alrijne Hospital, Leiden, The Netherlands.
  • Department of Neurology, Isala, Meppel, The Netherlands.
  • Department of Neurology, Maasstad Hospital, Rotterdam, The Netherlands.
  • Department of Neurology, Amphia, Breda, The Netherlands.

ORCID-Profile: Alyssa A Toorop, Mark Hj Wessels, Beatrijs Ha Wokke, Eva Mm Strijbis, Theo Rispens, Zoé LE van Kempen

Förderung

  • Stichting MS Research
  • Hersenstichting
  • Innovative Medicines Initiative
  • Innovatiefonds Zorgverzekeraars

Zitieren

APA

Toorop, A. A., Wessels, M. H., Boonkamp, L., Gelissen, L. M., Hoitsma, E., Zeinstra, E. M., van Rooij, L. C., van Munster, C. E., Vennegoor, A., Mostert, J. P., Wokke, B. H., Kalkers, N. F., Hoogervorst, E. L., van Eijk, J. J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J., …, & Teunissen, C. E. (2024). Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241293940

Vancouver

Toorop AA, Wessels MH, Boonkamp L, Gelissen LM, Hoitsma E, Zeinstra EM, et al. Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241293940

BibTeX
@article{Toorop2024,
  author = {Toorop, Alyssa A and Wessels, Mark Hj and Boonkamp, Lynn and Gelissen, Liza My and Hoitsma, E and Zeinstra, Esther Mpe and van Rooij, Luuk C and van Munster, Caspar Ep and Vennegoor, Anke and Mostert, Jop P and Wokke, Beatrijs Ha and Kalkers, Nynke F and Hoogervorst, Erwin Lj and van Eijk, Jeroen Jj and Roosendaal, Christiaan M and Kragt, Jolijn J and Eurelings, Marijke and van Genugten, Jessie and Nielsen, Jessica and Sinnige, Lgf and Kloosterziel, Mark E and Arnoldus, Edo Pj and van Dijk, Gert W and Bouvy, Willem H and Strijbis, Eva Mm and van Oosten, Bob W and de Jong, Brigit A and Uitdehaag, Bernard Mj and Rispens, Theo and Killestein, Joep and van Kempen, Zoé LE and Teunissen, Charlotte E},
  title = {Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients},
  journal = {Multiple Sclerosis Journal},
  year = {2024},
  doi = {10.1177/13524585241293940}
}
Kostenlos starten →